HONG KONG – HKEX-listed Innovent Biologics Inc. said its IBI-305 referencing Roche Holding AG's Avastin (bevacizumab) has met primary endpoints in two randomized, head-to-head trials, putting the company one step closer to bringing to market one of the first Avastin biosimilars approved in China. Read More
NEW DELHI – With record domestic approvals, active engagement in semi-regulated markets and a growing footprint in regulated markets, the Indian biosimilars industry is poised to hit the $40 billion mark by 2030, according to a new industry analysis report. Read More
HONG KONG – Chinese drugmakers' stocks hit their worst slump since 2008 last week on reports of a government pilot program aimed at lowering generic drug prices. Read More
HONG KONG – China's Bio-Thera Solutions Ltd. has launched the phase I trial of BAT-4306F, an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal antibody (MAb) that seeks to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma patients. Read More
Hitgen Ltd., of Chengdu, China, is collaborating with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, to use Hitgen's libraries of DNA-encoded compounds to find small-molecule leads for targets of interest. Hitgen will receive undisclosed technology access and research support payments and is eligible for milestone payments. Read More
HONG KONG – Chinese biosimilar maker Shanghai Henlius Biotech Inc. on Monday filed for an IPO on the Hong Kong Stock Exchange, making it the seventh pre-profit biotech firm in the listing queue, while four have gone public. Read More
HONG KONG – South Korean tech giant LG Corp.'s life sciences arm, LG Chem Ltd., has entered an agreement to develop and commercialize Avacta Group plc's multiple affimer candidates to treat inflammatory disorders and oncology. Read More
